Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.38 |
| ▸ | ESR1 | P03372 | 8/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404418 | 0.78 | CYP1A2 (0.48) | CYP1A2HSD17B10TDP1 | |
| SCHEMBL2094615 | 0.75 | TYMS (0.36) | — | |
| SCHEMBL2094560 | 0.75 | CYP2A6 (0.50) | CYP1A2CYP3A4 | |
| SCHEMBL2091623 | 0.75 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL670670 | 0.69 | CYP1A2 (0.52) | MCL1ESR2ESR1CYP1A2CYP3A4 | |
| SCHEMBL1097974 | 0.69 | CYP2A6 (0.48) | CYP1A2CYP3A4TSHRHIF1AHSD17B10 | |
| SCHEMBL1402659 | 0.68 | CYP1A2 (0.63) | MCL1ESR2ESR1CYP1A2CYP3A4 | |
| SCHEMBL5535303 | 0.67 | GRM5 (0.41) | CYP1A2CYP3A4ALOX15HSD17B10 | |
| SCHEMBL3480878 | 0.67 | CYP2A6 (0.60) | MCL1ESR2ESR1CYP1A2HSD17B10 | |
| SCHEMBL13251163 | 0.65 | MCL1 (0.46) | MCL1ESR2ESR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | MCL1 2641/4885ESR2 638/4885ESR1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.